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Abstract
Background: Relative quantification is a commonly used method for assessing gene expression, however its accuracy and
reliability is dependent upon the choice of an optimal endogenous control gene, and such choice cannot be made a priori.
There is limited information available on suitable reference genes to be used for studies involving human epicardial adipose
tissue. The objective of the current study was to evaluate and identify optimal reference genes for use in the relative
quantification of gene expression in human epicardial fat depots of lean, overweight and obese subjects.
Methodology/Principal Findings: Some of the commonly used reference genes including 18S, ACTB, RPL27, HPRT, CYCA,
GAPDH, RPLPO, POLR2A and B2M were quantified using real-time PCR analysis. The expression stability of these genes was
evaluated using Genorm, Normfinder and Bestkeeper algorithms. In addition, the effect of sample size on the validation
process was studied by randomly categorizing subjects in two cohorts of n=2 and n=33.
Conclusions/Significance: CYCA, GAPDH and RPL27 were identified as the most stable genes common to all three
algorithms and both sample sizes. Their use as reference gene pairs might contribute to the enhanced robustness of relative
quantification in the studies involving the human epicardial adipose tissue.
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Introduction
Human epicardial adipose tissue (EAT) is a visceral fat depot
that has gained significant attention in the recent times. Numerous
studies have reported significant positive correlations between
EAT mass and coronary artery disease (CAD) in humans [1,2,3].
In addition, significant correlation is reported between visceral
obesity and EAT mass [4,5]. The current paradigm thus remains
that increased EAT mass due to obesity increases the risk of
developing CAD. However, the underlying mechanisms explain-
ing this association remain unknown. EAT is a metabolically
active depot capable of secreting various adipokines and cytokines.
Moreover, it is located between myocardium and the inner layer
of visceral pericardium, thereby sharing close proximity and a
common blood supply with the underlying myocardium [6]. It is
likely that EAT affects the cardiac-function and -metabolism in a
paracrine manner. A number of recent studies have, thus,
investigated the association between EAT expression of various
adipokines, cytokines, oxidative stress- and inflammatory- markers
with CAD [7,8,9,10]. For these studies, relative quantification of
gene expression remains the method of choice. In addition, our
benign understanding of human EAT function would largely
depend upon future studies assessing gene expression in this fat
depot.
Relative quantification is an easy, quick and effective way of
assessing gene expression, however its level of accuracy is
dependent upon various experimental steps including handling
of tissues, RNA extraction, storage of isolated RNA, efficiency of
reverse transcription and amplification [11,12]. Thus, it is a
common practice to normalize the data against an endogenous
reference gene or housekeeping gene (HKG) in order to correct
for the potential experimental inaccuracies [13]. An ideal internal
reference gene or HKG would be universally valid exhibiting
stable expression across most sample types and experimental
conditions, such that any differences in its expression could reflect
upon the experimental variation leading to data correction.
However, the literature suggests that no such gene exists, infact,
the expression of the most commonly used HKGs can vary based
on the experimental conditions and chosen set up [14,15,16]. The
impact of using an unstable HKG can lead to erroneous results as
demonstrated previously by Dhehda et al. and others [17,18,19].
Thus, it is crucial to identify and validate the HKGs prior to their
use for normalization during specific experimental set ups.
To date, none of the studies dealing with human EAT has
reported on the evaluation of HKGs prior to their use.
Considering that differences in the expression of HKGs have
been reported between omental and subcutaneous tissues [20], it
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Tissue
  Tissuebecomes essential to validate the HKG to be used for the studies
involving human EAT since various regional fat depots differ in
their gene expression. In the current study, we have compared the
expression of 9 commonly used HKGs in the EAT of lean,
overweight and obese patients undergoing coronary artery bypass
grafting (CABG). We employed the commonly used approaches of
Genorm, Normfinder and Bestkeeper to identify the most stable
HKGs. In addition, we randomly categorized our subjects in two
cohorts of n=12 and n=33 in order to assess the impact of
sample size on the validation approaches. We report that CYCA,
GAPDH and RPL27 are among the most stably expressed HKGs
common to all 3 algorithms and both sample sizes in human EAT.
Results
All the subjects (n=33) included in the study underwent CABG.
Allofthem weredyslipidemic, 54.5%had hypertension, 30.3%had
diabetes, 24.2% had metabolic syndrome, 24.2% had peripheral
vascular disease (PVD) and 30.3% smoked. All of the subjects were
kept on statins and anticoagulants, 78.8% on beta-blockers, 51.5%
on angiotensin converting enzyme-inhibitors, 9.0% on angiotensin-
receptor blockers and 24.2% on oral hypoglycemic medication.
Basedontheirbodymassindex(BMI),thesubjectsweredividedinto
three categories of lean, overweight and obese. BMI and waist
circumference of the obese group was significantly higher than the
lean and overweight groups (P#0.05) (Table 1). However, other
clinical parameters including systolic- and diastolic- blood pressure,
mean arterial pressure, age, fasting plasma glucose, triglycerides,
total-,LDL-andHDL-cholesterolwerenotdifferentamongvarious
groups (Table 1).
In order to determine the expression stability of selected HKGs
across these patient groups, we begun with calculating their
respective PCR amplification efficiencies as the first step. The
cDNA from randomly chosen lean, overweight and obese subjects
were pooled, serially diluted and amplified for the preparation of a
standard curve. The slope of the standard curve was then used for
calculating PCR amplification efficiency according to the
expression: E=21+10
(21/slope). Table 2 lists the amplification
efficiency for each of the candidate HKG that ranged from 90–
100%. Next, Genorm, Normfinder and Bestkeeper algorithms
were employed to establish the expression stability of candidate
genes for the sample sizes of n=12 and n=33. Genorm algorithm
operates on the assumption that the ratio of two ideal reference
genes should be constant under different experimental conditions.
In contrast, Normfinder algorithm uses a model-based approach
for identifying the most stable genes based on least inter- and intra-
group expression variations. Bestkeeper identifies the most stable
genes based on the coefficient of correlation to the bestkeeper
index, which is generated by the geometric mean of the Ct values
of best candidate genes under study.
Genorm Analysis
Comparison of the raw non-normalized quantitative data using
genorm revealed that most candidate HKGs exhibited expression
stability (M) values below 0.5 for both sample sizes, suggesting that
all of the 9 genes under study had stable expression. However,
successive elimination of the least stable genes based on highest M-
values led to the identification of CYCA and RPL27 as the most
stable genes for n=12 (Figure 1A). In contrast, GAPDH and CYCA
turned out to be the most stable genes when n=33 was considered
(Figure 1B), suggesting that Genorm analysis is sensitive to sample
size. Indeed, the ranking of genes was different when either n=12
or n=33 was used for analysis (Figure 1A, Figure 1B), although for
both sample sizes RPL27, CYCA, ACTB and GAPDH exhibited
lowest M-values and hence the best expression stability.
In addition, Genorm calculated the number of optimal
reference genes to be used for the derivation of a normalization
factor (NF). With the pairwise variation calculated between two
sequential NFs (NFn and NFn+1), V2/3 exhibited the highest V-
value below the cut-off value of 0.15 for both sample sizes
(V=0.084 for n=12 and V=0.097 for n=33), indicating that use
of 2 genes for normalization is necessary, whereas addition of a
third gene is optional (Figure 1C, Figure 1D).
Normfinder Analysis
IncontrasttoGenorm,NormfinderidentifiedCYCAandACTBas
thegeneswithlowestS-valuesandhencetheleastvariationindexfor
n=12, whereas RPL27 and GAPDH had the lowest S-values for
n=33(Table3).However,comparisonoftheinter-andintra-group
variation among lean, overweight and obese subjects revealed
RPL27, CYCA and GAPDH to be the genes exhibiting lowest
variation and hence highest stability for both sample sizes of n=12
(Figure 2A) and n=33 (Figure 2B). Since Genorm and Normfinder
utilizedifferentapproachesforidentifyingstablegenes,theobserved
differences in rankings between these two algorithms would be
expected. However, considering that both assumptions are valid, a
correlation analysis between M-values (Genorm) and S-values
(Normfinder) for each candidate HKG was conducted such that
most stable genes common to both algorithms could be identified.
Indeed, CYCA, RPL27, ACTB and GAPDH clustered very closely on
thecorrelationgraphforbothsamplesizesofn=12(Figure3A)and
n=33 (Figure 3B), thereby representing the most stable genes
common to both Genorm and Normfinder.
Bestkeeper Analysis
In order to qualify the observations common to Genorm and
Normfinder, an independent approach used by the Bestkeeper
algorithm was employed. Interestingly, for both sample sizes,
CYCA, GAPDH, RPL27 and ACTB exhibited higher coefficient of
correlation (r) to the bestkeeper index, lower coefficient of variance
(CV) and standard deviation (SD), pointing towards their
expression stability (Table 4). Although POLR2A and B2M
Table 1. Clinical characteristics of the subjects in the cohort.
Clinical
characteristics Lean (n=9)
Overweight
(n=18) Obese (n=8)
Body mass
index (kg/m
2)
23.8 6 0.5
c 26.6 6 0.2
b 32.5 6 0.6
a
Waist circumference
(cm)
93.0 61.6
b 100.0 61.6
b 114.3 6 2.7
a
Age (years) 62 6 3.8 60 6 2.7 59.4 6 3.5
SBP (mmHg) 131.8 6 9.03 125.8 6 3.2 125.1 6 3.06
DBP (mmHg) 68 6 2.9 72.3 6 2.1 72.4 6 2.0
MAP (mmHg) 89.3 6 2.8 90.1 6 2.4 90.0 6 1.6
FPG (mM) 6.4 6 0.8 6.3 6 0.5 5.8 6 0.33
Total-cholesterol (mM) 4.1 6 0.36 3.8 6 0.18 3.7 6 0.4
LDL-cholesterol (mM) 2.3 6 0.3 2.1 6 0.16 1.8 6 0.17
HDL-cholestreol (mM) 1.3 6 0.2 1.1 6 0.06 1.1 6 0.09
Triglycerides (mM) 1.4 6 0.16 1.5 6 0.17 1.9 6 0.20
Superscripts represent statistically significant differences (P#0.05) determined
using one-way ANOVA and Tukey’s post-hoc analysis. SBP= systolic blood
pressure, DBP= diastolic blood pressure, MAP= mean arterial pressure, FPG=
fasting plasma glucose.
doi:10.1371/journal.pone.0032265.t001
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their higher CV- and SD-values (Table 4).
Impactofclinicalcharacteristicsofthepatients. Outofthe
3algorithms,onlyNormfinderiscapableofdeterminingthestability
ofcandidate reference genesbased onthe sampletype. Thus,we re-
assessed the stability of the candidate genes using Normfinder after
dividingthesubjectsintovariouscategoriesbasedontheirdiseaseand
medicationstatususingn=33.AsshowninTable5,CYCA,GAPDH
andRPL27wereinvariablyidentifiedasthemoststablegenesinour
cohortbasedontheirsmoking,PVD,diabetes,hypertension,MSand
medication status. Indeed, these data support our conclusion that a
combination of 2 genes out of CYCA, GAPDH and RPL27 would
representthemoststablereferencegenesacrossavarietyofconditions
for studies involving human EAT.
Table 2. Candidate reference genes with respective symbol, accession number, name, primer sequences and efficiency of
amplification (E).
Gene Symbol (Accession
Number) Gene Name Primer Sequence (59-39) E (%)
RPLPO (NM_001002) Ribosomal protein large P0
F: GGATTACACCTTCCCACTTGCT
R: GCCACAAAGGCAGATGGATCA
92
RPL27 (NM_000988) Ribosomal protein L27
F: GTGAAAGTGTATAACTACAATCACC
R: TCAAACTTGACCTTGGCCT
91
HPRT (NM_000194)
Hypoxanthine phosphoribosyl-
transferase 1
F: ACCCCACGAAGTGTTGGATA
R: AAGCAGATGGCCACAGAACT
91
B2M (NM_004048) Beta-2 microglobulin
F: GCTATCCAGCGTACTCCAAAG
R: CACACGGCAGGCATACTC
99
ACTB (NM_001101) Beta-actin
F: CATCCACGAAACTACCTTCAACTC
R: GCAATGATCTTGATCTTCATTGTG
95
18S (NR_003286) 18S ribosomal RNA
F: CAGCCACCCGAGATTGAGCA
R: TAGTAGCGACGGGCGGTGTG
99
POLR2A (NM_000937) RNA polymerase 2A
F: CTTCACGGTGCTGGGCATT
R: GTGCGGCTGCTTCCATAA
95
CYCA/PPIA (NM_021130) Peptidylprolyl isomerase A
F: ATCCTAGAGGTGGCGGATTT
R: CACTCAGGTCTGAGCCACAA
90
GAPDH (NM_002046)
Glycerladehyde 3-phosphate
dehydrogenase
F: ATGTTCGTCATGGGTGTGAA
R: GGTGCTAAGCAGTTGGTGGT
97
doi:10.1371/journal.pone.0032265.t002
Figure 1. Validation of candidate genes using Genorm. Genorm M-values of the candidate genes for (A) n=12 and (B) n=33. Pairwise
variation (V-values) of the candidate genes for (C) n=12 and (D) n=33. *represents the optimal number of reference genes required for the
calculation of normalization factor.
doi:10.1371/journal.pone.0032265.g001
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Relative quantification of gene expression remains the method of
choice, however its accuracy and reliability is critically dependent
upon the choice of endogenous control or HKG [21]. While the use
of an endogenous control is required for the correction of non-
biological and experimental variation, a non-optimal endogenous
control can either introduce pseudo-variation or mask the real
biological variation leading to misinterpretation of data. Thus, it is
essentialtouseanoptimalreferencegeneforrelativequantification.
However, there is no ‘‘ideal reference gene’’ that could qualify the
‘‘one fits all’’ scenario, since most of the commonly used reference
genes have been reported to be sensitive towards the experimental
conditions and system under investigation [14,15,16]. Thus, it is
advised to systematically validate the reference genes prior to their
use fornew experimental systems.In viewofthis,several algorithms
designed to identify the most stable genes were developed [22]. We
have used 3 of these very popular approaches, namely: Genorm,
Normfinder and Bestkeeper to compareand validate aset ofchosen
HKGs, such that optimal reference gene/s could be identified to be
usedintherelativequantificationstudiesinvolvinghumanEAT.An
ideal approach would be to perform a genome-wide survey of the
human EAT, in order to identify the potentially stable HKGs, prior
to implementing the validation process. However, due to the
complexity and expensive nature of this approach, we restricted
ourselvestothevalidationofasetofHKGsthatarecommonlyused
for studies involving EAT depots. In addition, considering the
practicality of the validation process for each new experimental set
up,wesoughttoidentifytheeffectofsamplesizeonthevalidationof
HKGs. We randomly selected n=4 from each of the lean,
overweightandobesegroupofsubjectsfromourcohortandcreated
two sample sizes of n=12 and n=33 that were followed separately
during the validation process.
Genorm algorithm uses a multiple pairwise comparison ap-
proach, where the expression stability (M) of a given gene is
calculated as the mean standard deviation of the log-transformed
expression ratios across samples relative to other reference genes
remaininginthegenepanel.Thisisfollowedbystepwiseexclusionof
Figure 2. Validation of candidate genes using Normfinder algorithm. Inter- and intra-group variation of each candidate gene for (A) n=12
and (B) n=33. Columns represent the inter-group variation, whereas the error bars represent the intra-group variation for each candidate gene.
doi:10.1371/journal.pone.0032265.g002
Table 3. Gene stability (S) values calculated by Normfinder.
Candidate Genes S-values (n=12) S-values (n=33)
CYCA 0.053 0.044
ACTB 0.061 0.044
RPL27 0.063 0.037
GAPDH 0.066 0.037
HPRT 0.102 0.071
POLR2A 0.108 0.087
B2M 0.109 0.055
18S 0.129 0.092
RPLPO 0.147 0.075
doi:10.1371/journal.pone.0032265.t003
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fromthepaneluntilreachingthelasttwogeneswiththesmallestM-
values (i.e. the most stable genes) [23]. Hellemens et al recommend
using M#0.5 for identifying most stable genes [24]. In addition,
Vandesompele et al. recognized the error that is introduced when
using a single HKG for normalization. Thus, in their landmark
paper they introduced a mathematical approach to determine the
optimalnumberofgenesrequiredforthecalculationofareliableNF
[23]. Genorm uses this approach to calculate pairwise variation (V)
between two sequential NFsi.e. NFnand NFn+1,until the variation
drops below the recommended threshold of 0.15. Below this
threshold, a larger v-value would indicate that the added gene has a
significant effect and should be included for the calculation of a
reliable NF. Using these parameters, Genorm identified that 2 most
stable HKGs would be required for the calculation of a NF for both
sample sizes. CYCA and RPL27 were recognized as the most stable
genes for a smaller sample size (n=12), whereas GAPDH and CYCA
were identified as the most stable genes for the larger sample size
(n=33). It is interesting to note that in each case, CYCA, RPL27,
GAPDH and ACTB were identified as the top 4 stable genes. Ling et
al. have previously reported altered expression stability/rankings of
candidate genes (with Genorm analysis) in different sample subsets
of Drosophila brains modeling aging related neurodegeneration,
even when the samples had similar tissue composition [25]. Ling et
al. thus concluded that expression stability of candidate HKGs is
sample- and analysis-specific. Since Genorm computes its M-values
based on expression ratio of candidate genes (multiple pair-wise
comparisons),itisindependentofvariationintheamountofstarting
material as well as of the normal distribution of data. However, it
does not correct for inter-group variation that is introduced when
working with heterogeneous populations. As mentioned before, we
begun with randomly selected (n=4) subjects for each category of
lean, overweight and obese subjects for n=12 analysis. Whereas
additionallean(n=5),overweight(n=12)andobese(n=4)subjects
were used for subsequent analysis of n=33. It is likely that
expression variation within each group of subjects could have led to
different gene rankings for each sample size in our study.
The issue of intra- and inter-group variation and its impact on
reference gene expression was addressed by Anderson et al [26].
They developed a model-based approach known as Normfinder to
identify candidate reference genes with least inter- and intra-
group variation. Thus, a stable reference gene according to
Normfinder would have an inter-group variation close to zero with
least intra-group variation. Interestingly, CYCA, GAPDH and
Table 5. Identification of most stable genes based on the
disease and medication status of the subjects using
Normfinder.
Condition Best gene S-values
Disease status
Smoking CYCA 0.029
Peripheral vascular disease GAPDH 0.042
Hypertension GAPDH 0.041
Diabetes RPL27 0.048
Metabolic syndrome* RPL27 0.032
Medication status
Beta-blockers RPL27 0.022
Angiotensin converting enzyme- inhibitors GAPDH 0.025
Angiotensin-receptor blockers GAPDH 0.023
Oral hypoglycemics RPL27 0.054
*Information related to metabolic syndrome was available for n=30.
doi:10.1371/journal.pone.0032265.t005
Figure 3. Determination of the stable genes common to both Genorm and Normfinder algorithms. Correlation analysis between M-
values (Genorm) and S-values (Normfinder) representing the expression stability of each candidate gene for (A) n=12 and (B) n=33. The r-value
signifies the coefficient of correlation. A P#0.05 was considered to be significant.
doi:10.1371/journal.pone.0032265.g003
Table 4. Coefficient of correlation (r), coefficient of variation
(CV) and standard deviation (SD) in the Ct values of each
candidate gene calculated by the Bestkeeper algorithm for
n=12 and n=33.
Candidate Genes N=12 N=33
R CV SD r CV SD
POLR2A 0.973 2.04 0.55 0.843 2.13 0.58
CYCA 0.966 0.97 0.22 0.845 1.40 0.32
GAPDH 0.916 1.72 0.40 0.931 1.67 0.39
ACTB 0.912 1.88 0.39 0.878 1.84 0.39
RPL27 0.897 1.58 0.35 0.853 1.42 0.32
B2M 0.858 2.23 0.44 0.902 2.26 0.45
HPRT 0.813 1.47 0.48 0.809 1.34 0.44
18S 0.701 1.96 0.33 0.486 1.84 0.32
RPLPO 0.687 1.97 0.41 0.742 1.82 0.38
doi:10.1371/journal.pone.0032265.t004
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intra-group variation for both sample sizes. However, the gene
rankings were different between Genorm and Normfinder.
Considering the different approaches used by Genorm and
Normfinder, it is expected that when two genes would exhibit
higher expression variation across samples/groups they would be
ranked lower with Normfinder even if their expression ratios do
not change, thereby receiving a better M-value with Genorm.
Since both of these approaches use valid assumptions, we
performed a correlation analysis to identify best HKGs that would
be common to both algorithms. Once again, CYCA, RPL27, ACTB
and GAPDH were identified as the best 4 genes clustering very
close on the correlation graph.
In contrast to Genorm and Normfinder, Bestkeeper analysis
chooses stable genes based on the low variation of expression
within the samples of tissue under study [27]. Bestkeeper calculates
the coefficient of correlation (r-values) between each candidate
gene and the bestkeeper index, which represents the geometric
mean of best candidate genes. Thus, a higher r-value would
correspond to stable expression of the candidate gene in the
chosen experimental set up. In addition, Bestkeeper calculates
standard deviation (SD) and coefficient of variation (CV) among
Ct values across samples that help to identify the stability of a
candidate gene. It is advised that a gene with SD value ,1, low
CV and higher r value would have stable expression across the
tested set of samples. All of the 9 tested genes exhibited SD values
,1, qualifying them as stable genes. However, CYCA, GAPDH,
RPL27 and ACTB were considered as the most stable genes due to
their higher r- and lower CV-values for both sample sizes. In
addition, when the data was re-analyzed using the disease and
medication status of patients in our cohort, CYCA, GAPDH and
RPL27 turned out to be the most stable genes out of a pool of 9
otherwise stable genes (as pointed by the Genorm M-values and
Bestkeeper SD values).
In conclusion, CYCA, GAPDH and RPL27 were identified as the
most stable reference genes common to Genorm, Normfinder and
BestkeeperalgorithmsforstudiesinvolvinghumanEAT,notonlyin
context of obesity but also under a variety of other conditions.
Indeed, a combination of 2 genes out of these 3 genes would
contributetoenhancedrobustnessofrelativequantificationanalysis
thereby impacting our current and future understanding of the
epicardial fat depot in humans.
Methods
Ethics Statement
The study was approved by the ethics committee of the Institut
Universitaire de Cardiologie et de Pneumologie de Que ´bec. A
written informed consent was obtained from all participants.
Samples
EAT corresponds to the adipose depot in direct contact with the
heartlocatedbetweenthemyocardiumandthevisceralpericardium.
EAT samples were collected from 33 patients undergoing CABG at
the Institut Universitaire de Cardiologie et de Pneumologie de
Que ´bec, QC, Canada. The patients were divided into lean (n=9,
BMI,25.0),overweight(n=16;BMI.25.0–30.0)andobese(n=8;
BMI.30.0) based on the BMI criteria used by the World Health
Organization. The samples were collected in liquid nitrogen during
the CABG procedure and storedat 280
uCuntil further analysis.
Selection of Reference genes
Candidate reference genes commonly used for the data normal-
ization in the studies involving epicardial and other adipose tissues
were selected for validation. These genes included: 18S [7,8,28,29],
B2M[30,31],CYCA[32,33,34],HPRT[35],GAPDH[36,37,38,39],
ACTB [10,40,41], RPLPO [42], RPL27 [43,44] and POLR2A
[45,46,47].
RNA extraction, reverse transcription and Quantitative
PCR
Total RNA was isolated from 100 mg of tissue using the RNeasy
LipidTissueMiniKit(QIAGEN,Mississauga,Ontario)accordingto
manufacturer’s instructions. Purity of total RNA was determined as
260/280 nmabsorbanceratiowithexpectedvaluesbetween1.8–2.0
usingaMultiskanSpectrum(ThermoScientific,Milford,MA,USA).
Inaddition,RNAintegrityofrandomlyselectedsamples(n=12)was
assessed using the Bio-Rad Experion (Bio-Rad Laboratories, ON,
Canada). Five hundred ng of extracted total RNA was reverse
transcribed using Expand Reverse Transcriptase (Roche Diagnos-
tics, Montreal, QC, Canada) according to the manufacturer’s
instructions.ThecDNAwasdiluted1:20inDNase-freewaterbefore
usingforquantificationbyreal-timequantitative PCR(qPCR).The
real-time PCR mixture was prepared using SYBRH Green
JumpStart
TM Taq ReadyMix
TM (#S5193, Sigma Aldrich, USA)
accordingtothemanufacturer’sinstructions.TheprimersforqPCR
were designed using AlleleID (PREMIER Biosoft International,
USA) and synthesized commercially (Invitrogen, USA). All primers
wereconfirmedusingtheNCBIBlasttoolagainstallavailablemRNA
sequencestoensurespecificity.Thesequenceforeachsetofprimersis
giveninTable2.TheqPCRwasperformedina384-wellplateformat
usingtheABI-7900 HTFastReal-timesystem(AppliedBiosystems,
USA).At theend ofeachrun, melting curveanalysis wasperformed
andafewrepresentativesampleswererunonagarosegeltoensurethe
specificity of the amplification. All samples were amplified in
duplicates from the same RNA preparation and the mean values
were used for further analysis.
Determination of reference gene expression stability
To assess the stability of candidate reference genes, 3 commonly
used approaches Genorm, Normfinder and Bestkeeper algorithms
were utilized. Genorm
plus was downloaded as part of the Qbase
plus
software available from http://medgen.ugent.be/ ˜jvdesomp/
genorm/. Normfinder was downloaded and used as an excel applet
from http://www.mdl.dk/publicationsnormfinder.htm. In addi-
tion, the Bestkeeper algorithm was downloaded from http://www.
gene-quantification.de/bestkeeper.html andusedasanexcelmacro
according to the developers instructions.
Statistical analysis
Clinical characteristics of patients were compared among
various groups using one-way ANOVA followed by Tukey’s post-
hoc analysis. Differences exhibiting a P#0.05 were considered
significant. Pearson’s correlation analysis was used to determine
the association between gene rankings obtained by Genorm and
Normfinder. All statistical analysis was performed using Graphpad
prism 5.0 software, La Jolla, CA, USA.
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